MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Urinary frequency, enuresis and incontinence

Drug Safety Update

 October 2015: Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events

 December 2014: Botulinum toxin products: rare but serious risks

NICE Guidance (also see drug-specific links below)

 CG97: Lower urinary tract symptoms in men: management, June 2015

 CG171: Urinary incontinence in women: management, updated November 2015

 CG148: Urinary incontinence in neurological disease: assessment and management, August 2012

 TA290: Mirabegron for treating symptoms of overactive bladder, June 2013

Not for use in the frail/elderly patient

Pack Price
56 tablet (8 x 7 tablets) £2.38
84 tablet (12 x 7 tablets) £3.68
Pack Price
56 tablet £17.91
Pack Price
56 tablet (8 x 7 tablets) £3.16
Pack Price
30 tablet £13.77
Pack Price
30 tablet £27.54
Pack Price
8 patch £27.20
Pack Price
150 ml £214.84
Pack Price
56 tablet (4 x 14 tablets) £13.75
Pack Price
56 tablet (4 x 14 tablets) £15.00
Pack Price
28 capsule (2 x 14 capsules) £12.89
Pack Price
28 tablet (2 x 14 tablets) £25.48
Pack Price
28 tablet (2 x 14 tablets) £25.48
Pack Price
28 tablet (4 x 7 tablets) £25.78
Pack Price
28 tablet (4 x 7 tablets) £25.78

Higher dose is much more expensive than other antimuscarinics - use for existing patients only

Pack Price
30 tablet (3 x 10 tablets) £27.62
Pack Price
30 tablet (3 x 10 tablets) £35.91

Mirabegron is the first in a new class of drugs it is a beta-3-adrenoceptor agonist. It is reserved for those patients for whom antimuscarinics are contraindicated or clinically ineffective, or have unacceptable side effects.

 

Pack Price
30 tablet (3 x 10 tablets) £29.00
Pack Price
30 tablet (3 x 10 tablets) £29.00